Risk Profiles of New Users of Oral Anticoagulants Between 2011 and 2019 in Germany
暂无分享,去创建一个
[1] R. Herings,et al. Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands , 2023, Drugs - Real World Outcomes.
[2] A. Patrick,et al. Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study , 2022, BMJ Open.
[3] H. Crijns,et al. Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany , 2022, Drugs - Real World Outcomes.
[4] S. Hohnloser,et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study , 2021, European heart journal. Quality of care & clinical outcomes.
[5] J. Hallas,et al. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[6] Ana Catarina Fonseca,et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke , 2021, European stroke journal.
[7] G. Lip,et al. Comparative Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients , 2021, Stroke.
[8] A. Farcomeni,et al. Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a network metanalysis on 605,771 patients. , 2021, European heart journal. Cardiovascular pharmacotherapy.
[9] G. Thomalla,et al. Intravenöse Lyse-Therapie beim ischämischen Schlaganfall – Schritt für Schritt , 2020, Neurologie up2date.
[10] L. Paschke,et al. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study , 2020, BMC Medicine.
[11] G. Lippi,et al. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge , 2020, International journal of stroke : official journal of the International Stroke Society.
[12] J. Trocio,et al. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population , 2019, BMC Cardiovascular Disorders.
[13] L. Mbuagbaw,et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies , 2018, European Journal of Epidemiology.
[14] S. Hohnloser,et al. Effectiveness and Safety of Non–Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation , 2018, Thrombosis and Haemostasis.
[15] L. Friberg,et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation , 2017, Open Heart.
[16] S. Hohnloser,et al. Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study , 2017, Clinical Research in Cardiology.
[17] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[18] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.
[19] G. Lip,et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study , 2016, British Medical Journal.
[20] W. Olson,et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients , 2014, Current medical research and opinion.
[21] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[22] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[23] D. Atar,et al. Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trial , 2013 .
[24] Gregory Y H Lip,et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.
[25] G. Lip,et al. Identifying Patients at High Risk for Stroke Despite Anticoagulation: A Comparison of Contemporary Stroke Risk Stratification Schemes in an Anticoagulated Atrial Fibrillation Cohort , 2010, Stroke.
[26] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[27] B. Lewis,et al. Identifying patients at high risk for restenosis after percutaneous transluminal coronary angioplasty for unstable angina pectoris. , 1989, The American journal of cardiology.
[28] U. Rotermund. Leitfaden , 1922, Ausbruch aus der Komplexitätsfalle.
[29] U. Haug,et al. German Pharmacoepidemiological Research Database (GePaRD) , 2021 .
[30] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.